New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 26, 2014
09:49 EDTBCRXBioCryst, HHS extend peramivir agreement for 31 days
BioCryst Pharmaceuticals disclosed that it and the U.S. Department of Health and Human Services mutually agreed to extend their agreementís current expiration date of February 28 for 31 days. The new expiration date is changed to March 31. The extension of the agreement will allow ongoing stability testing of peramivir to continue beyond the current contract expiration date. All other terms and conditions of the agreement remain unchanged.
News For BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 2, 2015
06:28 EDTBCRXFujifilm CEO says 'ready' for large orders of Avigan drug for Ebola, WSJ reports
Fujifilmís (FUJIY) Avigan drug, which has shown signs of efficacy against the Ebola virus, has drawn interest from about 20 countries, The Wall Street Journal reports, citing comments made by CEO Shigetaka Komori. The drug was developed by Toyama Chemical, a Fujifilm unit, and Komori said the company is ready for large orders. Other drug companies that are working on experimental Ebola vaccines or treatments include Peregrine (PPHM), Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
February 27, 2015
13:24 EDTBCRXLiberia, U.S. begin ZMapp ebola trial
In partnership with the Liberian government, the National Institute of Allergy and Infectious Diseases launched a clinical trial to obtain safety and efficacy data on the investigational drug ZMapp as a treatment for Ebola virus disease. The study may be expanded to test ZMapp against other treatments which may also include the following: Tekmira siRNA from Tekmira Pharmaceuticals (TKMR), Favipiravir from Toyama Chemical, BCX4430 from BioCryst (BCRX), and AVI-7537 from Sarepta (SRPT). The trial is expected to conclude in December 2016.
February 18, 2015
06:58 EDTBCRXBioCryst sees FY15 operating expenses $75M-$95M
Subscribe for More Information
06:57 EDTBCRXBioCryst reports Q4 EPS (16c), consensus (21c)
Reports Q4 revenue $5.4M, consensus $3.64M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use